The upcoming PREVAIL interim analysis (Q4 2026, result Q1 2027) is a major binary catalyst. Positive outcome could drive significant upside, while failure would severely impact value. Regulatory decisions in 2H26 add further optionality. Monitor for any safety signals or efficacy trends in the interim data.
Price Chart
Executive Summary
NewAmsterdam Pharma reported Q1 2026 revenue of $3.0M (flat YoY) and a net loss of $48.4M, widening from $39.5M. The key catalyst is the planned PREVAIL interim analysis in Q4 2026 with results expected in Q1 2027, plus regulatory decisions in 2H26 for obicetrapib. Cash remains strong at $707.3M.
Key Financial Metrics
Key Facts
- Cash, cash equivalents and marketable securities of $707.3M at March 31, 2026
- Revenue of $3.0M for Q1 2026 (flat vs Q1 2025)
- Net loss of $48.4M for Q1 2026 vs $39.5M in Q1 2025
- PREVAIL interim analysis planned for Q4 2026, result expected in Q1 2027
- Regulatory decisions from EMA, UK, and Switzerland expected in 2H26
- Completed enrollment in REMBRANDT (323 patients); RUBENS topline data expected year-end 2026
Financial Impact
Net loss increased by $8.9M YoY; cash burn rate ~$21.6M per month in Q1 2026
Risk Factors
- PREVAIL interim analysis may not show sufficient efficacy for early stopping
- Regulatory approval in Europe could be delayed or denied
- Cash burn continues without near-term revenue; need for further financing before PREVAIL readout
- Competition from existing lipid-lowering therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210283 |
| Document: nams-20260507.htm | 0001193125-26-210283 |
| Document: 0001193125-26-210283-index-headers.html | 0001193125-26-210283 |
| Document: 0001193125-26-210283-index.html | 0001193125-26-210283 |
| Document: 0001193125-26-210283.txt | 0001193125-26-210283 |
| 8-K Data (Synthetic) | 0001193125-26-210283 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 17w ago | 8-K | $24.90 $16.51 | ▼ −33.68% | ▼ −36.18% | $12.65 (−49.19%) |
May 7, 2026 21w ago | 8-K | $22.80 $15.00 | ▼ −34.21% | ▼ −38.04% | $12.65 (−44.52%) |
Apr 24, 2026 23w ago | 8-K | $19.10 $19.38 | ▲ +1.47% | ▼ −3.31% | $12.65 (−33.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access